Skip to content

    Recently Viewed

      Listening...

      FINAL Lede- Janssen AI- Abstract tech lede

      Can artificial intelligence change how we discover drugs?

      Yes—according to new research from scientists at Janssen who’ve found a way to speed up the drug discovery process using AI.

      Share Article
      share to

      Janssen Research & Development, part of the Johnson & Johnson family of companies, has been at the forefront of treatment innovation for decades.

      In fact, Dr. Paul Janssen, the Belgian physician who founded his eponymous company in 1953, discovered and developed dozens of lifesaving medications throughout his career.

      Traditionally, the process of discovering new pharmaceuticals takes years, due to the vast amount of data scientists must comb through to first identify the chemical compounds that are most likely to help treat a targeted disease—before they can even begin testing their effectiveness.

      But a recent paper published in the journal Cell Chemical Biology presented an exciting development when it comes to drug discovery: Janssen scientists have found a new way to leverage artificial intelligence (AI)—using computer systems to perform certain tasks that normally require human intelligence, also known as “machine learning"—to help speed up the process.

      How AI is reinventing drug discovery

      In a typical drug discovery experiment, cells representing a specific disease, such as lung cancer, are exposed to a variety of compounds, and a microscopy snapshot is taken of each reaction that follows.

      There’s so much unmet need out there. Our algorithms can help us better mine our information to find better treatments faster.
      Hugo Ceulemans

      One such experiment might generate half a million snapshots. Scientists commonly use AI to help sort through them, with the goal of finding a compound that could create the desired reaction for the disease they are studying.

      However, there hasn’t been a way to use the data gathered from those snapshots to inform later experiments for other diseases. Realizing how valuable it would be to recycle these learnings, Janssen researchers teamed up with academic partners from leading European universities to develop computer algorithms that scientists can now use to predict how other types of cells will likely react to the same compounds, giving them a leg up when starting a new study.

      “We no longer have to start from scratch every time,” explains Hugo Ceulemans, Scientific Director, Discovery Sciences, Janssen Research & Development, and a senior author of the study.

      In fact, Ceulemans and his team found this AI method to be up to 250 times more efficient than the traditional method of drug discovery.

      “There’s so much unmet need out there when it comes to medications,” Ceulemans says. “Our algorithms can help us better mine our information to find better treatments faster.”

      Read the 2017 Janssen U.S. Transparency Report

      Access the full report, including videos from company leaders discussing how Janssen works each day to transform patients’ lives.

      More from Johnson & Johnson

      Innovation
      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      Latest news
       Biomedical scientist Robert Langer headshot

      Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research

      Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
      Health & wellness
       Blue latex gloved hand pointing at a brain MRI scan to pinpoint brain circuits associated with depression symptoms

      Is this the end of one-size-fits-all treatments for depression?

      Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.